Mortality and Second Cancer Incidence After Treatment for Testicular Cancer: Psychosocial Health and Lifestyle Are Modifiable Prognostic Factors

PURPOSE To evaluate whether selected modifiable patient-reported adverse health outcomes (AHOs) in testicular cancer survivors (TCSs) represent prognostic factors of overall mortality, cancer mortality, and first-time non–germ cell second cancer (SecCa) incidence. PATIENTS AND METHODS In 775 long-term TCSs (diagnosis: 1980-1994) who previously participated in a quality-of-life survey, 20-year mortality and SecCa incidence were compared between the surgery group (n = 272) and TCSs after platinum-based chemotherapy (PBCT; n = 503). A PBCT standard group (total cisplatin: ≤ 630 mg: n = 124) was separated from a PBCT high subgroup (total cisplatin: > 630 mg; n = 379). Univariate and multivariate analyses (Kaplan-Meier; Cox proportional hazard analyses) included age, treatment, and prior major physical comorbidity as nonmodifiable factors, whereas low socioeconomic status, unhealthy lifestyle, probable depression disorder, and neurotoxicity were modifiable AHOs. RESULTS For all TCSs, the cumulative overall 20-year mortality was 14% (95% CI, 11.8 to 16.8). Rising age, PBCT high, and comorbidity significantly increased the risk of overall mortality rate. Compared with a low-risk group (no AHO; n = 446) and with exception of neurotoxicity, this risk was further significantly enhanced by 80% in TCSs of a medium-risk group (one or two AHOs; n = 278). In men of a high-risk group (three AHOs; n = 47), the probability of overall mortality and of cancer mortality was eight-fold and five-fold increased, respectively. Risk grouping did not influence on SecCa incidence. CONCLUSION Self-reported unfavorable modifiable AHO concerning lifestyle and psychosocial health are in TCSs independently and significantly associated with increased overall mortality and cancer mortality. Health professionals and the TCSs themselves, particularly those after PBCT high, should continuously be aware of these risk factors attempting maximal reduction of these AHOs and thereby supporting long-term survival.

[1]  S. Fosså,et al.  Testicular Cancer in the Cisplatin Era: Causes of Death and Mortality Rates in a Population-Based Cohort , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. Gupta,et al.  Long-Term Mental Health Service Utilization Among Survivors of Testicular Cancer: A Population-Based Cohort Study. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Gopal K Singh,et al.  The Association Between Psychological Distress and Cancer Mortality in the United States: Results from the 1997-2014 NHIS-NDI Record Linkage Study. , 2021, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[4]  G. Daugaard,et al.  Long-term neurotoxicity and quality of life in testicular cancer survivors—a nationwide cohort study , 2020, Journal of Cancer Survivorship.

[5]  S. Schlesinger,et al.  Dose–response relationship between physical activity and mortality in adults with noncommunicable diseases: a systematic review and meta-analysis of prospective observational studies , 2020, International Journal of Behavioral Nutrition and Physical Activity.

[6]  C. Otte,et al.  Comorbid depression in medical diseases , 2020, Nature Reviews Disease Primers.

[7]  M. Taphoorn,et al.  Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up†. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Thomas J. Smith,et al.  Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Fosså,et al.  Risk of positive selection bias in longitudinal surveys among cancer survivors: Lessons learnt from the national Norwegian Testicular Cancer Survivor Study. , 2020, Cancer epidemiology.

[10]  S. Fosså,et al.  Continuing increased risk of second cancer in long‐term testicular cancer survivors after treatment in the cisplatin era , 2020, International journal of cancer.

[11]  S. Fosså,et al.  Thromboembolic events after high‐intensity training during cisplatin‐based chemotherapy for testicular cancer: Case reports and review of the literature , 2020, International journal of cancer.

[12]  Chad A. LaGrange,et al.  Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[13]  C. Johansen,et al.  Psychological stress in long-term testicular cancer survivors: a Danish nationwide cohort study , 2019, Journal of Cancer Survivorship.

[14]  J. Witjes,et al.  Platinum exposure and cause‐specific mortality among patients with testicular cancer , 2019, Cancer.

[15]  C. Matthews,et al.  Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable , 2019, Medicine and science in sports and exercise.

[16]  S. Katikireddi,et al.  Depression and anxiety among people living with and beyond cancer: a growing clinical and research priority , 2019, BMC Cancer.

[17]  F. Saad,et al.  Contemporary North-American population-based validation of the International Germ Cell Consensus Classification for metastatic germ cell tumors of the testis , 2019, World Journal of Urology.

[18]  P. Nathan,et al.  Association of Exercise With Mortality in Adult Survivors of Childhood Cancer , 2018, JAMA oncology.

[19]  J. Witjes,et al.  Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Berney,et al.  ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  K. Courneya,et al.  Effects of high-intensity interval training on fatigue and quality of life in testicular cancer survivors , 2018, British Journal of Cancer.

[22]  S. Fosså,et al.  Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Fosså,et al.  Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors , 2018, Advances in urology.

[24]  C. Johansen,et al.  The Hospital Anxiety and Depression Scale (HADS) and the 9‐item Patient Health Questionnaire (PHQ‐9) as screening instruments for depression in patients with cancer , 2017, Cancer.

[25]  G David Batty,et al.  Psychological distress in relation to site specific cancer mortality: pooling of unpublished data from 16 prospective cohort studies , 2017, British Medical Journal.

[26]  C. Johansen,et al.  Second Malignant Neoplasms and Cause of Death in Patients With Germ Cell Cancer: A Danish Nationwide Cohort Study. , 2016, JAMA oncology.

[27]  C. Bokemeyer,et al.  Symptom burden in long-term germ cell tumor survivors , 2016, Supportive Care in Cancer.

[28]  M. Stockler,et al.  The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study , 2016, Journal of Cancer Survivorship.

[29]  S. Fosså,et al.  Long-term Relative Survival after Diagnosis of Testicular Germ Cell Tumor , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[30]  S. Fosså,et al.  Chronic fatigue in 812 testicular cancer survivors during long-term follow-up: increasing prevalence and risk factors. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  S. Fosså,et al.  Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  F. Mols,et al.  Depressive symptoms are a risk factor for all-cause mortality: results from a prospective population-based study among 3,080 cancer survivors from the PROFILES registry , 2013, Journal of Cancer Survivorship.

[33]  M. Vercelli,et al.  Socio-economic inequalities: a review of methodological issues and the relationships with cancer survival. , 2013, Critical reviews in oncology/hematology.

[34]  S. Fosså,et al.  Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  B. Nes,et al.  Exercise patterns and peak oxygen uptake in a healthy population: the HUNT study. , 2012, Medicine and science in sports and exercise.

[36]  K. Schmitz,et al.  Cancer, physical activity, and exercise. , 2012, Comprehensive Physiology.

[37]  Sameer M. Siddiqi,et al.  Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. , 2012, Journal of the National Cancer Institute.

[38]  S. Palmer,et al.  Health behaviors among testicular cancer survivors. , 2012, The Journal of community and supportive oncology.

[39]  A. Sood,et al.  Biobehavioral Factors and Cancer Progression: Physiological Pathways and Mechanisms , 2011, Psychosomatic medicine.

[40]  M. Ro̸rth,et al.  Progressive Resistance Training and Cancer Testis (PROTRACT) - Efficacy of resistance training on muscle function, morphology and inflammatory profile in testicular cancer patients undergoing chemotherapy: design of a randomized controlled trial , 2011, BMC Cancer.

[41]  A. Mykletun,et al.  Concurrent validity of the CAGE questionnaire. The Nord-Trøndelag Health Study. , 2011, Addictive behaviors.

[42]  R. Souchon,et al.  Interdisciplinary Evidence-Based Recommendations for the Follow-Up of Testicular Germ Cell Cancer Patients , 2011, Oncology Research and Treatment.

[43]  E. Weiderpass Lifestyle and cancer risk. , 2010, Journal of preventive medicine and public health = Yebang Uihakhoe chi.

[44]  P. Spiess,et al.  Testis cancer survivors' health behaviors: comparison with age-matched relative and demographically matched population controls. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  R. Bremnes,et al.  Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  M. Gospodarowicz Testicular cancer patients: considerations in long-term follow-up. , 2008, Hematology/oncology clinics of North America.

[47]  S. Fosså,et al.  Scale for Chemotherapy-induced Long-term Neurotoxicity (SCIN): Psychometrics, Validation, and Findings in a Large Sample of Testicular Cancer Survivors , 2006, Quality of Life Research.

[48]  G. Rustin,et al.  Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial , 2005, The Lancet.

[49]  D. Dearnaley,et al.  Fertility, gonadal and sexual function in survivors of testicular cancer , 2005, British Journal of Cancer.

[50]  M. Williams,et al.  Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17) , 2005, British Journal of Cancer.

[51]  A. Mykletun,et al.  Study of anxiety disorder and depression in long-term survivors of testicular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  A. Mykletun,et al.  Depression in relation to age and gender in the general population: the Nord‐Trøndelag Health Study (HUNT) , 2001, Acta psychiatrica Scandinavica.

[53]  A. Gulsvik,et al.  Cigarette smoking gives more respiratory symptoms among women than among men The Nord-Trøndelag Health Study (HUNT) , 2000, Journal of epidemiology and community health.

[54]  S. Fosså,et al.  A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma , 2000, British Journal of Cancer.

[55]  E. Arnesen,et al.  Impact of body weight on blood pressure with a focus on sex differences: the Tromso Study, 1986-1995. , 2000, Archives of internal medicine.

[56]  R Sylvester,et al.  Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  L. Collette,et al.  Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  S. Fosså,et al.  Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  M. Williams,et al.  Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  S. Fosså,et al.  Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group. , 1995, British Journal of Cancer.

[61]  S. Fosså,et al.  Original article: BOP/VIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours , 1991 .

[62]  S. Fosså,et al.  Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. , 1989, The Journal of urology.

[63]  L. Einhorn,et al.  Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. , 1987, The New England journal of medicine.

[64]  J. Ewing,et al.  Detecting alcoholism. The CAGE questionnaire. , 1984, JAMA.

[65]  R. Snaith,et al.  The Hospital Anxiety And Depression Scale , 2003, Health and quality of life outcomes.

[66]  L. Einhorn Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. , 1981, Cancer research.

[67]  A. Barrett,et al.  COMBINED MANAGEMENT OF MALIGNANT TERATOMA OF THE TESTIS , 1979, The Lancet.

[68]  S. Rossetti,et al.  Health-related quality of life and psychosocial implications in testicular cancer survivors. A literature review. , 2018, European review for medical and pharmacological sciences.

[69]  L. Sheppard,et al.  Contribution of health behaviors to the association between area-level socioeconomic status and cancer mortality. , 2016, Social science & medicine.

[70]  Arnulf Langhammer,et al.  The Nord-Trøndelag Health Study 1995-97 (HUNT 2): Objectives, contents, methods and participation , 2003 .

[71]  G. Mead,et al.  The International Germ Cell Consensus Classification: a new prognostic factor-based staging classification for metastatic germ cell tumours. , 1997, Clinical oncology (Royal College of Radiologists (Great Britain)).

[72]  S. Fosså,et al.  Management of patients with poor-prognosis nonseminomatous germ cell cancer. , 1990, Oncology.

[73]  R. Gray A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[74]  S. Fosså,et al.  Unilateral retroperitoneal lymph node dissection in patients with non-seminomatous testicular tumor in clinical stage I. , 1984, European urology.